Jaka jest cena za Algernon Pharmaceuticals Inc. (AGN)

Cena za Algernon Pharmaceuticals Inc. (AGN) wynosi $0.29357476

Jaka jest kapitalizacja rynkowa dla Algernon Pharmaceuticals Inc. (AGN)

Kapitalizacja rynkowa dla Algernon Pharmaceuticals Inc. (AGN) wynosi $1.02M

Algernon Pharmaceuticals Inc. (AGN) Dywidendy

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Rok	Dywidenda (skorygowana o podziały akcji)	Zmień
Za mało danych dla podanych dat.

Rok

Dywidenda (skorygowana o podziały akcji)

Zmień

Za mało danych dla podanych dat.

Rok	Dywidenda	Zmień
Za mało danych dla podanych dat.

Rok

Dywidenda

Zmień

Za mało danych dla podanych dat.

Firma	Liczba wypłat dywidend	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	0.00%	US
Argenx SE ARGX.US	0.00%	NL
Lonza Group AG LONN.SW	0.00%	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	KR
UCB S.A. UCB.BR	29.00%	BE

Firma

Liczba wypłat dywidend

Kraj